Vanguard Group Inc. Grows Position in Arvinas, Inc. (NASDAQ:ARVN)

Vanguard Group Inc. raised its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN) by 0.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 7,062,561 shares of the company’s stock after purchasing an additional 56,561 shares during the period. Vanguard Group Inc. owned 10.28% of Arvinas worth $135,389,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. KBC Group NV increased its holdings in Arvinas by 77.0% during the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock valued at $55,000 after buying an additional 1,255 shares during the period. KLP Kapitalforvaltning AS purchased a new position in shares of Arvinas in the 4th quarter valued at $171,000. Teacher Retirement System of Texas raised its position in shares of Arvinas by 19.0% in the 4th quarter. Teacher Retirement System of Texas now owns 14,295 shares of the company’s stock worth $274,000 after acquiring an additional 2,280 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in shares of Arvinas by 10.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 14,570 shares of the company’s stock worth $279,000 after purchasing an additional 1,367 shares during the last quarter. Finally, LPL Financial LLC boosted its position in Arvinas by 12.5% during the fourth quarter. LPL Financial LLC now owns 18,669 shares of the company’s stock valued at $358,000 after purchasing an additional 2,077 shares in the last quarter. Institutional investors own 95.19% of the company’s stock.

Analyst Upgrades and Downgrades

ARVN has been the subject of several analyst reports. BMO Capital Markets set a $20.00 price target on shares of Arvinas and gave the company an “outperform” rating in a research report on Wednesday, March 12th. Wedbush cut shares of Arvinas from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $57.00 to $12.00 in a research report on Wednesday, March 12th. Citigroup cut their price target on shares of Arvinas from $28.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday, March 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a report on Friday, February 7th. Finally, Stifel Nicolaus dropped their target price on Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. Five investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.50.

Insider Buying and Selling at Arvinas

In other Arvinas news, CEO John G. Houston sold 31,338 shares of Arvinas stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.72, for a total value of $523,971.36. Following the completion of the transaction, the chief executive officer now owns 1,157,480 shares of the company’s stock, valued at approximately $19,353,065.60. The trade was a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ian Taylor sold 9,020 shares of the company’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the transaction, the insider now owns 159,121 shares of the company’s stock, valued at approximately $2,658,911.91. This trade represents a 5.36 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,230 shares of company stock worth $769,402. Insiders own 5.23% of the company’s stock.

Arvinas Trading Down 2.9 %

Shares of NASDAQ:ARVN opened at $6.37 on Tuesday. Arvinas, Inc. has a twelve month low of $6.00 and a twelve month high of $39.34. The company’s 50 day moving average is $13.91 and its 200 day moving average is $19.87. The company has a market cap of $438.08 million, a PE ratio of -2.30 and a beta of 2.30.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same quarter in the previous year, the firm earned ($2.53) earnings per share. Equities research analysts predict that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.